Value Sense
IDXX
IDEXX Laboratories, Inc. (IDXX)
Last Price$437.20.0%
Market Cap$36.1B
LTM P/E
40.7x
EPS growth
8.5%
PEGY
4.8x
Peter Lynch Fair Value
$91.8
Overvalued (Peter Lynch formula)
(79.0%)
Stock quality
7/10
Great
IDXX
is 49.8% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

IDXX Peter Lynch Fair Value

Peter Lynch Fair Value Assumptions

as of Mar 10, 2025
LTM P/E
40.7x
EPS growth
8.5%
Dividend Yield
0.0%
PEGY
4.8x
Last share price
$437.2
Peter Lynch Fair Value
$91.8
79% overvalued

Peter Lynch Fair Value Calculation

PEGY
4.8x
=
LTM P/E
40.7x
/
(
EPS growth
8.54%
+
Dividend yield
0.00%
)
Peter Lynch
Fair Value
$91.8
=
Last share price
$437.2
/
PEGY
4.8x

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

IDXX EPS growth & Dividend Yield

Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
EPS growth
Dividend Yield

IDXX vs Peer Set: Peter Lynch Fair Value Comparison

General

PETER LYNCH FAIR VALUE

Financial metrics

Company name

Undervaluation / Overvaluation

Revenue growth

EBITDA margin

Net Income margin

IDEXX Laboratories, Inc. logo
IDEXX Laboratories, Inc.IDXX
(79.0%)
8.7%
25.2%
23.1%
Median Peer Set
(0.5%)
(6.5%)
14.0%
Thermo Fisher Scientific Inc. logo
Thermo Fisher Scientific Inc.TMO
(29.3%)
(4.6%)
(12.4%)
14.0%
Mettler-Toledo International Inc. logo
Mettler-Toledo International Inc.MTD
(75.4%)
2.2%
12.7%
22.3%
IQVIA Holdings Inc. logo
IQVIA Holdings Inc.IQV
32.5%
2.8%
2.4%
8.9%
Danaher Corporation logo
Danaher CorporationDHR
(17.5%)
(0.1%)
(17.9%)
16.3%
Quest Diagnostics Incorporated logo
Quest Diagnostics IncorporatedDGX
(34.0%)
(6.4%)
(6.5%)
9.2%
Waters Corporation logo
Waters CorporationWAT
(74.8%)
(0.5%)
(7.9%)
21.7%
Agilent Technologies, Inc. logo
Agilent Technologies, Inc.A
(37.1%)
(4.7%)
5.0%
19.8%
Natera, Inc. logo
Natera, Inc.NTRA
(50.2%)
32.0%
(32.1%)
(40.2%)
Illumina, Inc. logo
Illumina, Inc.ILMN
N/A
(2.9%)
4.6%
(28.0%)

Explore more intrinsic value tools hub for IDXX

Margin of safety
Ben Graham Fair Value
Earnings growth model
Discount rate
Peter Lynch charts
Reverse DCF
Earnings Power Value
Intrinsic Value
DCF value calculator
Relative Value

FAQ

What is IDEXX Laboratories, Inc. fair value by Peter Lynch formula?

As of Mar 03, 2025, IDEXX Laboratories, Inc.'s fair value using the Peter Lynch formula is $91.8 per share. The current price of $437.2 suggests IDEXX Laboratories, Inc. may be overvalued by this metric.

What is IDEXX Laboratories, Inc. Price to Earnings (P/E) ratio?

As of Mar 03, 2025, IDEXX Laboratories, Inc.'s P/E ratio is 40.7x. This is calculated by dividing the current share price of $437.2 by the Earnings per Share (EPS) for the trailing twelve months, which is $10.8. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.

What is IDEXX Laboratories, Inc. earnings per share (EPS)?

IDEXX Laboratories, Inc. earnings per share (EPS) for the twelve months ending Mar 03, 2025, was $10.8, a 8.5% growth year-over-year.